AN2 Therapeutics to Participate at Upcoming Investor Conferences
Details of the events are as follows:
Guggenheim 3rd Annual
-
Eric Easom , Co-Founder, Chairman, President and CEO, will participate in a fireside chat onMonday, November 9, 2026 at9:30am ET , and members of management will be available for 1X1 meetings.
Stifel 2026 Healthcare Conference,
-
Eric Easom , Co-Founder, Chairman, President and CEO, will provide a corporate overview onTuesday, November 10, 2026 at8:40am ET , and members of management will be available for 1X1 meetings.
-
Members of management will be available for 1X1 meetings on
Tuesday, November 17, 2026 .
Webcasts of the presentation and fireside chat can be accessed on the Investors section of the
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261020849168/en/
COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com
INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
ir@an2therapeutics.com
Source: AN2 Therapeutics, Inc.